社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
TAN PS
IP属地：未知
+关注
帖子 · 20
帖子 · 20
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
TAN PS
TAN PS
·
2022-01-21
OK👌
3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>
These three COVID-19 stocks could rake in a tremendous amount of cash this year.
3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>
看
3,669
回复
评论
点赞
1
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2022-01-21
OK👌
Stocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote>
Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high
Stocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote>
看
2,293
回复
评论
点赞
1
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2022-01-19
Ok👌
外媒头条：一次加息50个基点！市场预期越发激进
全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“
外媒头条：一次加息50个基点！市场预期越发激进
看
4,948
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-28
Ok,goood
看
2,476
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-27
Ok, great idea
看
3,110
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-27
Okokok☺️☺️☺️
看
2,556
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-26
Ok
非常抱歉，此主贴已删除
看
2,734
回复
1
点赞
4
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-25
Ok
非常抱歉，此主贴已删除
看
2,754
回复
1
点赞
8
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-24
Okokok good idea
看
2,746
回复
评论
点赞
1
编组 21备份 2
分享
举报
TAN PS
TAN PS
·
2021-12-24
Ok
非常抱歉，此主贴已删除
看
2,232
回复
评论
点赞
5
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582126034262927","uuid":"3582126034262927","gmtCreate":1619032504746,"gmtModify":1642212623813,"name":"TAN PS","pinyin":"tanpstanps","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":61,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":630345015,"gmtCreate":1642725433815,"gmtModify":1642725441780,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"OK👌","listText":"OK👌","text":"OK👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630345015","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://www.laohu8.com/m/news/1134509683?lang=zh_CN&edition=full","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<p><html><head></head><body>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>这是新的一年，新冠肺炎仍然和我们在一起。去年，我们看到医疗保健领域多种新冠疫苗和治疗方法获得了紧急使用授权。制药公司将在2022年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>（纽约证券交易所股票代码：PFE）是一家价值3100亿美元的大型公司，预计其新冠疫苗和抗病毒药物的销售额将不会是10亿或100亿美元，而是超过500亿美元。斗志昂扬<b>Novavax</b>（纳斯达克：NVAX）终于在全球范围内推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人<b>维尔生物技术</b>（纳斯达克：维尔）。对于这家小型生物技术公司来说，它的一种药物很容易成为价值10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的避风港</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·巴德威尔（辉瑞）：</b>辉瑞是新冠肺炎制药产品无可争议的冠军。仅在2022年，华尔街预计这家制药巨头的新型冠状病毒疫苗Comirnaty和口服抗病毒药物Paxlovid的销售额就将达到550亿美元。</blockquote></p><p>What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是，分析师开始接受Paxlovid可能在当前十年内成为该公司可持续收入来源的想法。当该药物上个月首次被美国食品和药物管理局根据紧急使用授权途径允许上市时，华尔街认为从商业角度来看，Paxlovid可能会在一年左右的时间内达到顶峰，然后随着疫情从视野中消失，销售额急剧下降。</blockquote></p><p>But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次获得批准还不到三周，令人痛苦的是，很明显，Paxlovid可能需要作为未来几年COVID-19最坏结果的故障保险。毕竟，高传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着，辉瑞应该是少数几家在新冠肺炎拥有可观、长期收入来源的大型制药商之一。反过来，在可预见的未来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及雄心勃勃的业务发展计划。</blockquote></p><p>So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此，如果您正在寻找一只能够抵御极高通胀和利率上升双重阻力的股票，辉瑞可能值得一试。</blockquote></p><p><b>Revenue forecasts for Novavax: $2 billion to $8 billion</b></p><p><blockquote><b>Novavax的收入预测：20亿至80亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax今年正处于伟大的边缘。该公司的股价跌至每股125美元。这就是它在2021年开始的地方，所以去年该股几乎遭受了洗盘。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在2月份，当Novavax报告其新冠疫苗的积极3期数据时，股价就飙升至300美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人说它的疫苗是同类产品中最好的，但扩大约20亿剂疫苗的合同生产说起来容易做起来难。这些现实导致该股较高点下跌约60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此，Novavax的收入已经达到了10亿美元大关，因此由于所有的预订，其疫苗甚至在获得批准之前就已经一鸣惊人。现在，全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度收益看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的生产能力。该公司预计将继续扩大规模，并预测2022年将分发20亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购了1亿剂疫苗），我们粗略计算出收入为320亿美元。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。尽管该公司对其价格保持沉默，但丹麦早在8月份就表示，根据欧盟(EU)协议，它为每剂疫苗支付了近21美元。欧盟已经订购了2亿剂，因此仅在欧洲的销售额就超过40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师非常保守，对Novavax 2022年的预测在20亿至80亿美元之间。（该公司的市值为90亿美元。）虽然一路上可能会出现一些问题，但Novavax肯定会在2022年从其COVID-19疫苗中赚取数十亿美元。如果该公司确实像其所说的那样交付20亿剂疫苗，该股可能会有大幅上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场全靠自己</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma（Vir Biotechnology）：</b>奥密克戎变种目前猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来公司</b>（bamlanivimab加etesevimab）以及来自<b>罗氏</b>和<b>再生</b>被认为对当前变体的活性显著降低。这样就只剩下一种对奥密克戎有效的输液了--<b>葛兰素史克</b>以及Vir Biotechnology的sotrovimab。这种单克隆抗体先前证明，在轻度至中度新冠肺炎和进展为重度疾病的高风险成人中，住院和死亡风险降低了79%。它是目前唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为唯一的单克隆抗体将有其特权。2021年前9个月，REGEN-COV带来了35亿美元的产品净销售额，而礼来公司的抗体组合带来了11.7亿美元。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院挤满了病人，任何有助于缓解系统压力的东西都可能受到高度追捧。</blockquote></p><p>And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的Paxlovid将极大地有利于减轻医疗保健系统的COVID-19负担，但这种口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像是常用处方药的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的止痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，表达了对Paxlovid可能的药物相互作用的担忧，这为sotrovimab继续广泛使用留下了充足的空间。根据与GSK的协议，Vir获得了sotrovimab销售额的72.5%，这家价值44亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2022-01-08 11:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>这是新的一年，新冠肺炎仍然和我们在一起。去年，我们看到医疗保健领域多种新冠疫苗和治疗方法获得了紧急使用授权。制药公司将在2022年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>（纽约证券交易所股票代码：PFE）是一家价值3100亿美元的大型公司，预计其新冠疫苗和抗病毒药物的销售额将不会是10亿或100亿美元，而是超过500亿美元。斗志昂扬<b>Novavax</b>（纳斯达克：NVAX）终于在全球范围内推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人<b>维尔生物技术</b>（纳斯达克：维尔）。对于这家小型生物技术公司来说，它的一种药物很容易成为价值10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的避风港</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·巴德威尔（辉瑞）：</b>辉瑞是新冠肺炎制药产品无可争议的冠军。仅在2022年，华尔街预计这家制药巨头的新型冠状病毒疫苗Comirnaty和口服抗病毒药物Paxlovid的销售额就将达到550亿美元。</blockquote></p><p>What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是，分析师开始接受Paxlovid可能在当前十年内成为该公司可持续收入来源的想法。当该药物上个月首次被美国食品和药物管理局根据紧急使用授权途径允许上市时，华尔街认为从商业角度来看，Paxlovid可能会在一年左右的时间内达到顶峰，然后随着疫情从视野中消失，销售额急剧下降。</blockquote></p><p>But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次获得批准还不到三周，令人痛苦的是，很明显，Paxlovid可能需要作为未来几年COVID-19最坏结果的故障保险。毕竟，高传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着，辉瑞应该是少数几家在新冠肺炎拥有可观、长期收入来源的大型制药商之一。反过来，在可预见的未来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及雄心勃勃的业务发展计划。</blockquote></p><p>So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此，如果您正在寻找一只能够抵御极高通胀和利率上升双重阻力的股票，辉瑞可能值得一试。</blockquote></p><p><b>Revenue forecasts for Novavax: $2 billion to $8 billion</b></p><p><blockquote><b>Novavax的收入预测：20亿至80亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax今年正处于伟大的边缘。该公司的股价跌至每股125美元。这就是它在2021年开始的地方，所以去年该股几乎遭受了洗盘。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在2月份，当Novavax报告其新冠疫苗的积极3期数据时，股价就飙升至300美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人说它的疫苗是同类产品中最好的，但扩大约20亿剂疫苗的合同生产说起来容易做起来难。这些现实导致该股较高点下跌约60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此，Novavax的收入已经达到了10亿美元大关，因此由于所有的预订，其疫苗甚至在获得批准之前就已经一鸣惊人。现在，全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度收益看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的生产能力。该公司预计将继续扩大规模，并预测2022年将分发20亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购了1亿剂疫苗），我们粗略计算出收入为320亿美元。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。尽管该公司对其价格保持沉默，但丹麦早在8月份就表示，根据欧盟(EU)协议，它为每剂疫苗支付了近21美元。欧盟已经订购了2亿剂，因此仅在欧洲的销售额就超过40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师非常保守，对Novavax 2022年的预测在20亿至80亿美元之间。（该公司的市值为90亿美元。）虽然一路上可能会出现一些问题，但Novavax肯定会在2022年从其COVID-19疫苗中赚取数十亿美元。如果该公司确实像其所说的那样交付20亿剂疫苗，该股可能会有大幅上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场全靠自己</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma（Vir Biotechnology）：</b>奥密克戎变种目前猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来公司</b>（bamlanivimab加etesevimab）以及来自<b>罗氏</b>和<b>再生</b>被认为对当前变体的活性显著降低。这样就只剩下一种对奥密克戎有效的输液了--<b>葛兰素史克</b>以及Vir Biotechnology的sotrovimab。这种单克隆抗体先前证明，在轻度至中度新冠肺炎和进展为重度疾病的高风险成人中，住院和死亡风险降低了79%。它是目前唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为唯一的单克隆抗体将有其特权。2021年前9个月，REGEN-COV带来了35亿美元的产品净销售额，而礼来公司的抗体组合带来了11.7亿美元。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院挤满了病人，任何有助于缓解系统压力的东西都可能受到高度追捧。</blockquote></p><p>And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的Paxlovid将极大地有利于减轻医疗保健系统的COVID-19负担，但这种口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像是常用处方药的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的止痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，表达了对Paxlovid可能的药物相互作用的担忧，这为sotrovimab继续广泛使用留下了充足的空间。根据与GSK的协议，Vir获得了sotrovimab销售额的72.5%，这家价值44亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","VIR":"Vir Biotechnology, Inc."},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax: $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"NVAX":0.9,"VIR":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630342483,"gmtCreate":1642725393521,"gmtModify":1642725393632,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"OK👌","listText":"OK👌","text":"OK👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630342483","repostId":"1138592368","repostType":4,"repost":{"id":"1138592368","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641997842,"share":"https://www.laohu8.com/m/news/1138592368?lang=zh_CN&edition=full","pubTime":"2022-01-12 22:30","market":"us","language":"en","title":"Stocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138592368","media":"Tiger Newspress","summary":"Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high","content":"<p><html><head></head><body>Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.</p><p><blockquote><html><head></head><body>周三股市上涨，投资者关注一份新的通胀报告，该报告显示复苏中的经济再次出现数十年来的最高价格涨幅。尽管如此，一天前，美联储主席杰罗姆·鲍威尔重申央行将根据需要进行干预以遏制物价上涨。</body></html></blockquote></p><p>The Bureau of Labor Statistics' December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November's already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.</p><p><blockquote>美国劳工统计局12月消费者价格指数(CPI)显示，2021年底物价同比上涨7.0%，创1982年以来最快涨幅。这与基于彭博社数据的普遍预期相符，并且较11月份本已高达6.8%的增幅有所加速。从环比来看，消费者价格上涨0.5%，略高于预期的0.4%，这是价格连续第十八个月上涨。</blockquote></p><p>Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.</p><p><blockquote>不包括食品和能源价格，所谓的消费者价格核心指标12月份比去年上涨5.5%，为1991年以来的最快涨幅。</blockquote></p><p>Wednesday's market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell's renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.</p><p><blockquote>周三的市场走势是在周二的反弹之后发生的，美联储主席杰罗姆·鲍威尔保证美联储将在必要时介入以缓解物价上涨，这至少暂时让市场松了一口气。在参议院银行委员会举行的鲍威尔重新提名听证会上，这位央行领导人重申，美联储将利用其政策工具降低通胀。</blockquote></p><p>“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.</p><p><blockquote>鲍威尔在听证会上表示：“如果我们看到通胀持续在高位，时间比预期的要长，如果我们不得不随着时间的推移进一步加息，那么我们就会加息。”</blockquote></p><p>The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.</p><p><blockquote>央行此前曾表示，今年计划加息三次，以将基准利率从目前接近零的水平上调。然而，一些华尔街顶级公司预测，鉴于当前的通胀背景，美联储将加息四次。</blockquote></p><p>But though Powell doubled down on the Fed's goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed's plan to begin shrinking its nearly $9 trillion balance sheet. The Fed's December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed's balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.</p><p><blockquote>但是，尽管鲍威尔加倍强调了美联储遏制通胀的目标，并将加息作为实现这一目标的工具，但他几乎没有进一步透露美联储开始缩减近9万亿美元资产负债表的计划。美联储上周的12月会议纪要显示，在近两年的资产购买之后，央行官员开始讨论缩减美联储的资产负债表，以帮助在疫情期间支撑市场。鲍威尔在听证会上重申，他预计资产负债表决选程序将于今年开始。</blockquote></p><p>"I think the biggest comment on most investors' minds that we talk to around the world would be a 'policy mistake' that the Fed might be too aggressive," Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday."Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that's what's calming investors."</p><p><blockquote>BMO资本市场首席投资策略师Brian Belski周二对雅虎财经直播表示：“我认为，在我们与世界各地的大多数投资者交谈时，最大的评论是美联储可能过于激进的‘政策错误’。”鲍威尔今天基本上出来说这将是一个过程...关于这需要多长时间，我认为这就是让投资者平静下来的原因。”</blockquote></p><p>Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday's session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.</p><p><blockquote>尽管借贷成本上升和金融状况收紧的前景引发了美国股市和科技股的波动，尤其是在最近几个交易日，但周二的交易日出现了逆转，以科技股为主的纳斯达克综合指数大幅跑赢大盘。</blockquote></p><p>"The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it's simply one of valuation," Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday."And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don't completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends."</p><p><blockquote>ProShares全球投资策略师西蒙·海曼(Simeon Hyman)周二对雅虎财经直播表示：“我认为，科技股的问题与其说是因为增长还很遥远，不如说是估值问题。”事实上，那些头重脚轻、市值最大的科技股在去年底和2022年初可能有点贵。但不要完全排除良好的增长故事，因为这是对抗通胀的最大防御。这是盈利和股息的增长。”</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2022-01-12 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.</p><p><blockquote><html><head></head><body>周三股市上涨，投资者关注一份新的通胀报告，该报告显示复苏中的经济再次出现数十年来的最高价格涨幅。尽管如此，一天前，美联储主席杰罗姆·鲍威尔重申央行将根据需要进行干预以遏制物价上涨。</body></html></blockquote></p><p>The Bureau of Labor Statistics' December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November's already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.</p><p><blockquote>美国劳工统计局12月消费者价格指数(CPI)显示，2021年底物价同比上涨7.0%，创1982年以来最快涨幅。这与基于彭博社数据的普遍预期相符，并且较11月份本已高达6.8%的增幅有所加速。从环比来看，消费者价格上涨0.5%，略高于预期的0.4%，这是价格连续第十八个月上涨。</blockquote></p><p>Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.</p><p><blockquote>不包括食品和能源价格，所谓的消费者价格核心指标12月份比去年上涨5.5%，为1991年以来的最快涨幅。</blockquote></p><p>Wednesday's market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell's renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.</p><p><blockquote>周三的市场走势是在周二的反弹之后发生的，美联储主席杰罗姆·鲍威尔保证美联储将在必要时介入以缓解物价上涨，这至少暂时让市场松了一口气。在参议院银行委员会举行的鲍威尔重新提名听证会上，这位央行领导人重申，美联储将利用其政策工具降低通胀。</blockquote></p><p>“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.</p><p><blockquote>鲍威尔在听证会上表示：“如果我们看到通胀持续在高位，时间比预期的要长，如果我们不得不随着时间的推移进一步加息，那么我们就会加息。”</blockquote></p><p>The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.</p><p><blockquote>央行此前曾表示，今年计划加息三次，以将基准利率从目前接近零的水平上调。然而，一些华尔街顶级公司预测，鉴于当前的通胀背景，美联储将加息四次。</blockquote></p><p>But though Powell doubled down on the Fed's goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed's plan to begin shrinking its nearly $9 trillion balance sheet. The Fed's December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed's balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.</p><p><blockquote>但是，尽管鲍威尔加倍强调了美联储遏制通胀的目标，并将加息作为实现这一目标的工具，但他几乎没有进一步透露美联储开始缩减近9万亿美元资产负债表的计划。美联储上周的12月会议纪要显示，在近两年的资产购买之后，央行官员开始讨论缩减美联储的资产负债表，以帮助在疫情期间支撑市场。鲍威尔在听证会上重申，他预计资产负债表决选程序将于今年开始。</blockquote></p><p>"I think the biggest comment on most investors' minds that we talk to around the world would be a 'policy mistake' that the Fed might be too aggressive," Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday."Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that's what's calming investors."</p><p><blockquote>BMO资本市场首席投资策略师Brian Belski周二对雅虎财经直播表示：“我认为，在我们与世界各地的大多数投资者交谈时，最大的评论是美联储可能过于激进的‘政策错误’。”鲍威尔今天基本上出来说这将是一个过程...关于这需要多长时间，我认为这就是让投资者平静下来的原因。”</blockquote></p><p>Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday's session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.</p><p><blockquote>尽管借贷成本上升和金融状况收紧的前景引发了美国股市和科技股的波动，尤其是在最近几个交易日，但周二的交易日出现了逆转，以科技股为主的纳斯达克综合指数大幅跑赢大盘。</blockquote></p><p>"The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it's simply one of valuation," Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday."And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don't completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends."</p><p><blockquote>ProShares全球投资策略师西蒙·海曼(Simeon Hyman)周二对雅虎财经直播表示：“我认为，科技股的问题与其说是因为增长还很遥远，不如说是估值问题。”事实上，那些头重脚轻、市值最大的科技股在去年底和2022年初可能有点贵。但不要完全排除良好的增长故事，因为这是对抗通胀的最大防御。这是盈利和股息的增长。”</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138592368","content_text":"Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.The Bureau of Labor Statistics' December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November's already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.Wednesday's market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell's renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.But though Powell doubled down on the Fed's goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed's plan to begin shrinking its nearly $9 trillion balance sheet. The Fed's December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed's balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.\"I think the biggest comment on most investors' minds that we talk to around the world would be a 'policy mistake' that the Fed might be too aggressive,\" Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.\"Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that's what's calming investors.\"Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday's session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.\"The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it's simply one of valuation,\" Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.\"And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don't completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.\"","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697404839,"gmtCreate":1642551869823,"gmtModify":1642551870152,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Ok👌","listText":"Ok👌","text":"Ok👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697404839","repostId":"2204841800","repostType":2,"repost":{"id":"2204841800","kind":"news","pubTimestamp":1642541820,"share":"https://www.laohu8.com/m/news/2204841800?lang=zh_CN&edition=full","pubTime":"2022-01-19 05:37","market":"us","language":"zh","title":"外媒头条：一次加息50个基点！市场预期越发激进","url":"https://stock-news.laohu8.com/highlight/detail?id=2204841800","media":"新浪财经","summary":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“","content":"<html><head></head><body><p><b>全球财经媒体昨夜今晨共同关注的头条新闻主要有：</b></p><blockquote><b>1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作</b></blockquote><blockquote><b>2、<a href=\"https://laohu8.com/S/MSFT\">微软</a>发起其史上最大规模收购 以近690亿美元收购<a href=\"https://laohu8.com/S/ATVI\">动视暴雪</a></b></blockquote><blockquote><b>3、<a href=\"https://laohu8.com/S/BLK\">贝莱德</a>CEO：美联储“激进”立场或导致收益率曲线趋平</b></blockquote><blockquote><b>4、原油飙升至2014年以来高点 拜登政府称正继续与产油国合作</b></blockquote><blockquote><b>5、研究显示omicron感染浪潮可能降低疫情未来的严重程度</b></blockquote><blockquote><b>6、2021年<a href=\"https://laohu8.com/S/AAPL\">苹果</a>手机占全球智能手机出货量22% 位居第一</b></blockquote><p><img src=\"https://static.tigerbbs.com/698315ff48290ccd4244f61fe7019f2b\" tg-width=\"550\" tg-height=\"369\" referrerpolicy=\"no-referrer\"/></p><p><b>货币市场预计美联储或一次升息50基点 将是2020年以来最大动作</b></p><p>货币市场价格显示，越来越多投资者预期美联储可能逾二十年来首次大规模提高借贷成本。</p><p>虽然加息25个基点仍是最有可能的情形，但掉期市场现在预计3月底前加息幅度将超过25个基点。鉴于本月政策会议预计不会有任何行动，这表明交易员至少正在考虑3月加息50个基点的可能性。自2000年5月以来， 美联储还从没有一口气加息这么多过。</p><p>近日来围绕美联储更大幅加息的猜测升温可能加剧了周二美国国债跌势。 <a href=\"https://laohu8.com/S/JPM\">摩根大通</a>首席执行官杰米·戴蒙上周警告美联储收紧政策可能不会像一些人预期的那样“和风细雨”，亿万富翁投资者Bill Ackman表示美联储应该在3月加息50个基点，以重建公信力。</p><p>CFTC最新持仓数据显示，对冲基金将净欧洲美元空头头寸提高至2018年12月以来最大水平，投机者对10年期国债期货的看空程度也达到2020年2月以来最高。</p><p><img src=\"https://static.tigerbbs.com/d7cad28562d81d8fed2fe8d732aa7112\" tg-width=\"550\" tg-height=\"296\" referrerpolicy=\"no-referrer\"/></p><p><b><a href=\"https://laohu8.com/S/MSFT\">微软</a>发起其史上最大规模收购 以近690亿美元收购<a href=\"https://laohu8.com/S/ATVI\">动视暴雪</a></b></p><p>微软宣布以687亿美元收购动视暴雪，促成视频游戏领域的两大巨头强强联合。</p><p>作为微软有史以来进行的最大一笔收购，该交易对这家美国最大游戏发行商之一的收购价为每股95美元现金。微软称，动视暴雪首席执行官Bobby Kotick将继续担任当前职位。交易完成后，动视暴雪业务将汇报给微软游戏部门负责人Phil Spencer。</p><p>交易完成后，微软将成为按营收计算的全球第三大游戏公司，仅次于<a href=\"https://laohu8.com/S/00700\">腾讯</a>和<a href=\"https://laohu8.com/S/SNE\">索尼</a>。</p><p>将动视暴雪热门游戏收入囊中，将有助于微软扩大其Xbox游戏机内容，提高对<a href=\"https://laohu8.com/S/SONY\">索尼</a>PlayStation的竞争力。动视暴雪与Xbox的合作由来已久。这家发行商最大一款游戏《使命召唤》的成功，很大程度上是得益于微软创新性的在线平台Xbox Live，该平台允许玩家联机进行多人对战。动视暴雪大多数游戏都在Xbox游戏机上发布。</p><p><img src=\"https://static.tigerbbs.com/733e77ab67cbbd3d5818c24cbcb9916a\" tg-width=\"550\" tg-height=\"366\" referrerpolicy=\"no-referrer\"/></p><p><b><a href=\"https://laohu8.com/S/BLK\">贝莱德</a>CEO：美联储“激进”立场或导致收益率曲线趋平</b></p><p>全球最大资产管理公司贝莱德CEO Larry Fink表示，美联储快速调整货币政策以遏制通胀可能会导致美国国债收益率曲线趋于平缓。</p><p>“我认为收益率曲线将会变平，如果美联储非常激进，我甚至可以看到一条负的收益率曲线，”Fink周二表示。</p><p>收益率曲线的形状揭示了投资者对美国经济增长和货币政策的预期。美联储计划早于预期加息的鹰派立场推高了短期利率，使曲线变平。</p><p>分析师通常认为，短期美国国债收益率与较长期美债收益率之差缩小（即收益率曲线趋平），是对经济增长和货币政策不确定性的担忧迹象。负的收益率曲线或曲线倒挂通常预示着经济衰退。</p><p>“收益率曲线的形状将成为决定经济的关键问题，”Fink说。</p><p><img src=\"https://static.tigerbbs.com/894b2f0869773330f31bbaf4cb56d3ec\" tg-width=\"550\" tg-height=\"365\" referrerpolicy=\"no-referrer\"/></p><p><b>原油飙升至2014年以来高点 拜登政府称正继续与产油国合作</b></p><p>油价升至七年高点之际，白宫称拜登政府正在与产油国合作，将确保供应达到足以满足需求的水平。</p><p>美国国家安全委员会发言人Emily Horne周二在一份声明中表示，白宫计划继续在全球经济增长的背景下监控能源价格，必要时会与OPEC+国家举行磋商。</p><p>Horne称，“我们会继续与产油国和消费国合作，这些措施已经对价格产生了实际影响，我们仍然保留可解决能源价格问题的工具” 。</p><p>汽油价格上涨一直是导致拜登任期内通胀飙升的主要因素，白宫千方百计降低汽油成本。油价上涨正在损害拜登的支持率，民主党在11月中期选举中保住两院多数党地位的难度加大。</p><p><img src=\"https://static.tigerbbs.com/504a7eb8073637bdb53e621b0dd905d0\" tg-width=\"550\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/></p><p><b>研究显示omicron感染浪潮可能降低疫情未来的严重程度</b></p><p>南非的研究人员表示，虽然omicron变种病毒引发一轮强烈的新冠疫情浪潮，但却可能会加速大流行病所造成各种干扰的终结，因为感染omicron的症状似乎较轻，并能提供针对德尔塔变种病毒的保护。</p><p>南非一个实验室将去年11月和12月感染omicron的23人作为样本进行的研究显示，虽然先前感染了德尔塔毒株的人可以感染omicron，但感染omicron株的人不会再感染德尔塔。</p><p>尽管omicron的感染力明显高于德尔塔，但包括南非在内的一些国家的医院和死亡率数据似乎表明，它导致的疾病严重程度较低。南非是最早出现omicron感染浪潮的国家。南非卫生研究所Alex Sigal等人的这项研究显示，omicron可以取代德尔塔毒株。</p><p>“这种取代的影响将取决于omicron的致病性是否确实低于德尔塔，”研究人员说。 “如果的确如此，那么Covid-19重症的发生率将降低，疫情对个人和社会的破坏性将会减弱。”</p><p><img src=\"https://static.tigerbbs.com/a45e0699fa17a3da9ad6e88c61dcc813\" tg-width=\"630\" tg-height=\"448\" referrerpolicy=\"no-referrer\"/></p><p><b>2021年<a href=\"https://laohu8.com/S/AAPL\">苹果</a>手机占全球智能手机出货量22% 位居第一</b></p><p>数据研究机构Canalys发布的最新报告显示，得益于iPhone 13的成功，苹果手机在2021年占全球智能手机出货量的22%，坐上全球智能手机市场的头把交椅，<a href=\"https://laohu8.com/S/SMSN.UK\">三星</a>以20%的市场份额紧随其后。此外，小米以12%排名第三，OPPO以9%排名第四，vivo以8%排名前五。</p><p>报告显示，截至2021年底，苹果手机占全球智能手机出货量的22%。Canalys指出，苹果上一次在智能手机市场排名第一是在2020年第四季度。</p><p>Canalys分析师Sanyam Chaurasia在一份声明中表示：“苹果iPhone新旗舰机在中国市场表现十分强劲。”“苹果的供应链开始复苏，但由于关键零部件短缺，苹果在第四季度仍被迫减产，无法生产足够的iPhone来满足需求。”</p></body></html>","source":"XLCJ","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>外媒头条：一次加息50个基点！市场预期越发激进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n外媒头条：一次加息50个基点！市场预期越发激进\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-19 05:37 北京时间 <a href=https://finance.sina.com.cn/stock/usstock/c/2022-01-19/doc-ikyamrmz6036284.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“激进”立场或导致收益率曲线趋平4、原油飙升至2014年以来高点 拜登政府称正继续与产油国合作5、研究显示omicron感染浪潮可能降低疫情未来的严重程度6、2021年苹果手机占全球智能手机出货量22%...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2022-01-19/doc-ikyamrmz6036284.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/02a85629f2a809e4eabd8677140a5f70","relate_stocks":{".SPX":"S&P 500 Index","BK4504":"桥水持仓",".IXIC":"NASDAQ Composite","BK4559":"巴菲特持仓",".DJI":"道琼斯","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2022-01-19/doc-ikyamrmz6036284.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204841800","content_text":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“激进”立场或导致收益率曲线趋平4、原油飙升至2014年以来高点 拜登政府称正继续与产油国合作5、研究显示omicron感染浪潮可能降低疫情未来的严重程度6、2021年苹果手机占全球智能手机出货量22% 位居第一货币市场预计美联储或一次升息50基点 将是2020年以来最大动作货币市场价格显示，越来越多投资者预期美联储可能逾二十年来首次大规模提高借贷成本。虽然加息25个基点仍是最有可能的情形，但掉期市场现在预计3月底前加息幅度将超过25个基点。鉴于本月政策会议预计不会有任何行动，这表明交易员至少正在考虑3月加息50个基点的可能性。自2000年5月以来， 美联储还从没有一口气加息这么多过。近日来围绕美联储更大幅加息的猜测升温可能加剧了周二美国国债跌势。 摩根大通首席执行官杰米·戴蒙上周警告美联储收紧政策可能不会像一些人预期的那样“和风细雨”，亿万富翁投资者Bill Ackman表示美联储应该在3月加息50个基点，以重建公信力。CFTC最新持仓数据显示，对冲基金将净欧洲美元空头头寸提高至2018年12月以来最大水平，投机者对10年期国债期货的看空程度也达到2020年2月以来最高。微软发起其史上最大规模收购 以近690亿美元收购动视暴雪微软宣布以687亿美元收购动视暴雪，促成视频游戏领域的两大巨头强强联合。作为微软有史以来进行的最大一笔收购，该交易对这家美国最大游戏发行商之一的收购价为每股95美元现金。微软称，动视暴雪首席执行官Bobby Kotick将继续担任当前职位。交易完成后，动视暴雪业务将汇报给微软游戏部门负责人Phil Spencer。交易完成后，微软将成为按营收计算的全球第三大游戏公司，仅次于腾讯和索尼。将动视暴雪热门游戏收入囊中，将有助于微软扩大其Xbox游戏机内容，提高对索尼PlayStation的竞争力。动视暴雪与Xbox的合作由来已久。这家发行商最大一款游戏《使命召唤》的成功，很大程度上是得益于微软创新性的在线平台Xbox Live，该平台允许玩家联机进行多人对战。动视暴雪大多数游戏都在Xbox游戏机上发布。贝莱德CEO：美联储“激进”立场或导致收益率曲线趋平全球最大资产管理公司贝莱德CEO Larry Fink表示，美联储快速调整货币政策以遏制通胀可能会导致美国国债收益率曲线趋于平缓。“我认为收益率曲线将会变平，如果美联储非常激进，我甚至可以看到一条负的收益率曲线，”Fink周二表示。收益率曲线的形状揭示了投资者对美国经济增长和货币政策的预期。美联储计划早于预期加息的鹰派立场推高了短期利率，使曲线变平。分析师通常认为，短期美国国债收益率与较长期美债收益率之差缩小（即收益率曲线趋平），是对经济增长和货币政策不确定性的担忧迹象。负的收益率曲线或曲线倒挂通常预示着经济衰退。“收益率曲线的形状将成为决定经济的关键问题，”Fink说。原油飙升至2014年以来高点 拜登政府称正继续与产油国合作油价升至七年高点之际，白宫称拜登政府正在与产油国合作，将确保供应达到足以满足需求的水平。美国国家安全委员会发言人Emily Horne周二在一份声明中表示，白宫计划继续在全球经济增长的背景下监控能源价格，必要时会与OPEC+国家举行磋商。Horne称，“我们会继续与产油国和消费国合作，这些措施已经对价格产生了实际影响，我们仍然保留可解决能源价格问题的工具” 。汽油价格上涨一直是导致拜登任期内通胀飙升的主要因素，白宫千方百计降低汽油成本。油价上涨正在损害拜登的支持率，民主党在11月中期选举中保住两院多数党地位的难度加大。研究显示omicron感染浪潮可能降低疫情未来的严重程度南非的研究人员表示，虽然omicron变种病毒引发一轮强烈的新冠疫情浪潮，但却可能会加速大流行病所造成各种干扰的终结，因为感染omicron的症状似乎较轻，并能提供针对德尔塔变种病毒的保护。南非一个实验室将去年11月和12月感染omicron的23人作为样本进行的研究显示，虽然先前感染了德尔塔毒株的人可以感染omicron，但感染omicron株的人不会再感染德尔塔。尽管omicron的感染力明显高于德尔塔，但包括南非在内的一些国家的医院和死亡率数据似乎表明，它导致的疾病严重程度较低。南非是最早出现omicron感染浪潮的国家。南非卫生研究所Alex Sigal等人的这项研究显示，omicron可以取代德尔塔毒株。“这种取代的影响将取决于omicron的致病性是否确实低于德尔塔，”研究人员说。 “如果的确如此，那么Covid-19重症的发生率将降低，疫情对个人和社会的破坏性将会减弱。”2021年苹果手机占全球智能手机出货量22% 位居第一数据研究机构Canalys发布的最新报告显示，得益于iPhone 13的成功，苹果手机在2021年占全球智能手机出货量的22%，坐上全球智能手机市场的头把交椅，三星以20%的市场份额紧随其后。此外，小米以12%排名第三，OPPO以9%排名第四，vivo以8%排名前五。报告显示，截至2021年底，苹果手机占全球智能手机出货量的22%。Canalys指出，苹果上一次在智能手机市场排名第一是在2020年第四季度。Canalys分析师Sanyam Chaurasia在一份声明中表示：“苹果iPhone新旗舰机在中国市场表现十分强劲。”“苹果的供应链开始复苏，但由于关键零部件短缺，苹果在第四季度仍被迫减产，无法生产足够的iPhone来满足需求。”","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":1,".DJI":1}},"isVote":1,"tweetType":1,"viewCount":4948,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696638036,"gmtCreate":1640677949442,"gmtModify":1640677949520,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Ok,goood","listText":"Ok,goood","text":"Ok,goood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696638036","isVote":1,"tweetType":1,"viewCount":2476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696076550,"gmtCreate":1640587154486,"gmtModify":1640587154568,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Ok, great idea","listText":"Ok, great idea","text":"Ok, great idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696076550","isVote":1,"tweetType":1,"viewCount":3110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698712448,"gmtCreate":1640541251767,"gmtModify":1640541251767,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Okokok☺️☺️☺️","listText":"Okokok☺️☺️☺️","text":"Okokok☺️☺️☺️","images":[{"img":"https://static.tigerbbs.com/a253a16a74a2b4e30af15fc0fad7fd1b","width":"1599","height":"899"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698712448","isVote":1,"tweetType":1,"viewCount":2556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":698424747,"gmtCreate":1640503796905,"gmtModify":1640503796987,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698424747","repostId":"2193781141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698214842,"gmtCreate":1640404859740,"gmtModify":1640404859857,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698214842","repostId":"2193720178","repostType":2,"isVote":1,"tweetType":1,"viewCount":2754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698820820,"gmtCreate":1640343733999,"gmtModify":1640344031317,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Okokok good idea","listText":"Okokok good idea","text":"Okokok good idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698820820","isVote":1,"tweetType":1,"viewCount":2746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698867692,"gmtCreate":1640343626830,"gmtModify":1640343654207,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582126034262927","idStr":"3582126034262927"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698867692","repostId":"2193414198","repostType":2,"isVote":1,"tweetType":1,"viewCount":2232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}